Share Price and Basic Stock Data
Last Updated: December 4, 2025, 2:47 am
| PEG Ratio | 3.11 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ganga Pharmaceuticals Ltd operates in the pharmaceuticals sector, a field that has seen varying fortunes over the years. As of the latest reporting, the company’s stock price stood at ₹11.7, with a market capitalization of ₹6.90 Cr. Over the past few years, revenue growth has been modest but somewhat erratic. Sales recorded for FY 2025 were ₹2.48 Cr, a slight decline from ₹2.58 Cr in FY 2024. Notably, quarterly sales figures have shown some fluctuations, with the latest reported quarter (September 2023) achieving ₹1.32 Cr, which reflects a consistency when compared to the previous quarter. However, the overall sales trend appears to lack the robust growth one might expect in a thriving pharmaceutical market, raising questions about Ganga Pharmaceuticals’ competitive positioning and market share.
Profitability and Efficiency Metrics
Profitability metrics for Ganga Pharmaceuticals reveal a challenging landscape. The company reported a net profit of ₹0.08 Cr for FY 2025, translating to a net profit margin of just 2.99%. This is significantly lower than what many investors would consider optimal, particularly in an industry ripe with potential. The operating profit margin (OPM) has been erratic, with the latest quarter showing a meager 3.79%. The return on equity (ROE) at a mere 1.13% and return on capital employed (ROCE) at 3.18% suggest that the company is struggling to generate adequate returns on its investments. Compounding these issues is a cash conversion cycle (CCC) of 403.19 days, indicating a long duration before cash is realized from sales, which can strain liquidity and operational efficiency.
Balance Sheet Strength and Financial Ratios
Turning to Ganga Pharmaceuticals’ balance sheet, it appears reasonably stable but not without its concerns. The company reported total borrowings of ₹1.56 Cr against reserves of ₹2.37 Cr, which implies a manageable debt-to-equity ratio of about 0.19. This suggests that the company is not heavily leveraged, a positive trait for investors wary of financial distress. However, the interest coverage ratio (ICR) of 1.79x indicates that while the company can meet its interest obligations, it is operating close to the edge. Furthermore, the price-to-book value (P/BV) ratio stands at 0.68x, which may imply that the stock is undervalued relative to its net assets, although this could also reflect market skepticism about the company’s growth potential.
Shareholding Pattern and Investor Confidence
In terms of shareholding, Ganga Pharmaceuticals has seen a notable shift. Promoters’ stake has declined from 66.71% in mid-2021 to 50.91% as of September 2025, while public shareholding has risen to 49.09%. This shift could indicate a growing acceptance of public investors but may also raise concerns about insider confidence in the company’s future prospects. With a relatively small number of shareholders—366 as of the latest report—liquidity could be a concern for potential investors. The lack of Foreign Institutional Investors (FIIs) or Domestic Institutional Investors (DIIs) involvement further underscores the cautious sentiment surrounding the stock, which could impact its volatility and market perception.
Outlook, Risks, and Final Insight
Looking ahead, Ganga Pharmaceuticals presents a mixed bag of opportunities and risks. On one hand, the pharmaceutical sector is generally seen as resilient, and if the company can streamline its operations and improve profitability, there could be upside potential. However, the current financial metrics suggest that the company is underperforming relative to its peers, and the long cash conversion cycle is a significant red flag. Investors might also be wary of the declining promoter stake, interpreting it as a lack of confidence from those closest to the business. Overall, while Ganga Pharmaceuticals may offer some value at its current price point, potential investors should carefully weigh these risks against the company’s capabilities in navigating the challenges ahead. Those considering an investment might want to keep an eye on operational improvements and shifts in market sentiment that could affect the stock’s trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ganga Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,580.44 Cr | 1,173.08 | 51.95 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2019 | Mar 2020 | Sep 2020 | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.38 | 1.70 | 1.14 | 1.23 | 1.25 | 1.24 | 1.35 | 1.23 | 1.32 | 1.42 | 1.31 | 1.33 |
| Expenses | 1.10 | 1.60 | 1.07 | 1.28 | 1.23 | 1.23 | 1.28 | 1.30 | 1.27 | 1.41 | 1.42 | 1.33 |
| Operating Profit | 0.28 | 0.10 | 0.07 | -0.05 | 0.02 | 0.01 | 0.07 | -0.07 | 0.05 | 0.01 | -0.11 | 0.00 |
| OPM % | 20.29% | 5.88% | 6.14% | -4.07% | 1.60% | 0.81% | 5.19% | -5.69% | 3.79% | 0.70% | -8.40% | 0.00% |
| Other Income | 0.08 | 0.09 | 0.07 | 0.19 | 0.11 | 0.15 | 0.12 | 0.18 | 0.09 | 0.15 | 0.29 | 0.14 |
| Interest | 0.12 | 0.12 | 0.09 | 0.10 | 0.10 | 0.09 | 0.12 | 0.07 | 0.09 | 0.09 | 0.09 | 0.09 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 |
| Profit before tax | 0.21 | 0.04 | 0.02 | 0.01 | 0.00 | 0.04 | 0.04 | 0.01 | 0.02 | 0.05 | 0.07 | 0.03 |
| Tax % | 23.81% | 25.00% | 50.00% | 100.00% | 25.00% | 25.00% | 0.00% | 50.00% | 20.00% | 57.14% | -66.67% | |
| Net Profit | 0.16 | 0.03 | 0.02 | 0.00 | 0.00 | 0.03 | 0.03 | 0.01 | 0.02 | 0.03 | 0.02 | 0.06 |
| EPS in Rs | 0.39 | 0.07 | 0.05 | 0.00 | 0.00 | 0.07 | 0.07 | 0.02 | 0.05 | 0.06 | 0.04 | 0.12 |
Last Updated: May 31, 2025, 5:58 am
Below is a detailed analysis of the quarterly data for Ganga Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 1.33 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Sep 2024) to 1.33 Cr., marking an increase of 0.02 Cr..
- For Expenses, as of Mar 2025, the value is 1.33 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.42 Cr. (Sep 2024) to 1.33 Cr., marking a decrease of 0.09 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.00 Cr.. The value appears strong and on an upward trend. It has increased from -0.11 Cr. (Sep 2024) to 0.00 Cr., marking an increase of 0.11 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value appears strong and on an upward trend. It has increased from -8.40% (Sep 2024) to 0.00%, marking an increase of 8.40%.
- For Other Income, as of Mar 2025, the value is 0.14 Cr.. The value appears to be declining and may need further review. It has decreased from 0.29 Cr. (Sep 2024) to 0.14 Cr., marking a decrease of 0.15 Cr..
- For Interest, as of Mar 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.09 Cr..
- For Depreciation, as of Mar 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.03 Cr.. The value appears to be declining and may need further review. It has decreased from 0.07 Cr. (Sep 2024) to 0.03 Cr., marking a decrease of 0.04 Cr..
- For Tax %, as of Mar 2025, the value is -66.67%. The value appears to be improving (decreasing) as expected. It has decreased from 57.14% (Sep 2024) to -66.67%, marking a decrease of 123.81%.
- For Net Profit, as of Mar 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Sep 2024) to 0.06 Cr., marking an increase of 0.04 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.12. The value appears strong and on an upward trend. It has increased from 0.04 (Sep 2024) to 0.12, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.66 | 2.44 | 2.45 | 2.63 | 2.73 | 3.18 | 2.99 | 2.27 | 2.32 | 2.47 | 2.58 | 2.48 |
| Expenses | 2.43 | 2.19 | 2.15 | 2.32 | 2.41 | 2.76 | 2.61 | 2.24 | 2.28 | 2.47 | 2.53 | 2.60 |
| Operating Profit | 0.23 | 0.25 | 0.30 | 0.31 | 0.32 | 0.42 | 0.38 | 0.03 | 0.04 | 0.00 | 0.05 | -0.12 |
| OPM % | 8.65% | 10.25% | 12.24% | 11.79% | 11.72% | 13.21% | 12.71% | 1.32% | 1.72% | 0.00% | 1.94% | -4.84% |
| Other Income | 0.15 | 0.17 | 0.14 | 0.16 | 0.15 | 0.14 | 0.17 | 0.25 | 0.26 | 0.30 | 0.24 | 0.44 |
| Interest | 0.30 | 0.33 | 0.33 | 0.32 | 0.28 | 0.25 | 0.24 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 |
| Profit before tax | 0.05 | 0.05 | 0.07 | 0.11 | 0.13 | 0.26 | 0.26 | 0.04 | 0.06 | 0.05 | 0.06 | 0.09 |
| Tax % | 40.00% | 40.00% | 28.57% | 27.27% | 23.08% | 30.77% | 23.08% | 50.00% | 16.67% | 40.00% | 33.33% | 11.11% |
| Net Profit | 0.03 | 0.03 | 0.05 | 0.07 | 0.09 | 0.19 | 0.19 | 0.02 | 0.04 | 0.04 | 0.05 | 0.08 |
| EPS in Rs | 0.13 | 0.13 | 0.12 | 0.17 | 0.22 | 0.47 | 0.47 | 0.05 | 0.10 | 0.10 | 0.10 | 0.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 66.67% | 40.00% | 28.57% | 111.11% | 0.00% | -89.47% | 100.00% | 0.00% | 25.00% | 60.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 66.67% | -26.67% | -11.43% | 82.54% | -111.11% | -89.47% | 189.47% | -100.00% | 25.00% | 35.00% |
Ganga Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -4% |
| 3 Years: | 2% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | -16% |
| 3 Years: | 26% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 13% |
| 1 Year: | -25% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:55 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.33 | 2.33 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.06 | 4.84 | 4.84 | 5.91 |
| Reserves | 0.28 | 0.31 | 0.74 | 0.81 | 0.91 | 1.09 | 1.29 | 1.31 | 1.35 | 1.39 | 2.21 | 2.29 | 2.37 |
| Borrowings | 2.07 | 2.14 | 2.19 | 2.14 | 2.05 | 1.87 | 1.47 | 1.73 | 1.93 | 1.83 | 1.36 | 1.42 | 1.56 |
| Other Liabilities | 0.46 | 0.61 | 0.35 | 0.60 | 1.22 | 0.74 | 0.75 | 0.56 | 0.66 | 0.71 | 0.24 | 0.42 | 0.32 |
| Total Liabilities | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
| Fixed Assets | 0.65 | 0.65 | 0.62 | 0.62 | 0.82 | 0.80 | 0.76 | 0.72 | 0.68 | 0.64 | 0.61 | 0.66 | 0.66 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.50 | 0.00 | 0.00 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.00 | 0.00 |
| Other Assets | 4.44 | 4.69 | 6.22 | 6.99 | 7.42 | 6.87 | 6.72 | 6.85 | 7.23 | 7.26 | 7.95 | 8.31 | 9.50 |
| Total Assets | 5.14 | 5.39 | 7.34 | 7.61 | 8.24 | 7.76 | 7.57 | 7.66 | 8.00 | 7.99 | 8.65 | 8.97 | 10.16 |
Below is a detailed analysis of the balance sheet data for Ganga Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 5.91 Cr.. The value appears strong and on an upward trend. It has increased from 4.84 Cr. (Mar 2025) to 5.91 Cr., marking an increase of 1.07 Cr..
- For Reserves, as of Sep 2025, the value is 2.37 Cr.. The value appears strong and on an upward trend. It has increased from 2.29 Cr. (Mar 2025) to 2.37 Cr., marking an increase of 0.08 Cr..
- For Borrowings, as of Sep 2025, the value is 1.56 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1.42 Cr. (Mar 2025) to 1.56 Cr., marking an increase of 0.14 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.32 Cr.. The value appears to be improving (decreasing). It has decreased from 0.42 Cr. (Mar 2025) to 0.32 Cr., marking a decrease of 0.10 Cr..
- For Total Liabilities, as of Sep 2025, the value is 10.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.66 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.66 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 9.50 Cr.. The value appears strong and on an upward trend. It has increased from 8.31 Cr. (Mar 2025) to 9.50 Cr., marking an increase of 1.19 Cr..
- For Total Assets, as of Sep 2025, the value is 10.16 Cr.. The value appears strong and on an upward trend. It has increased from 8.97 Cr. (Mar 2025) to 10.16 Cr., marking an increase of 1.19 Cr..
Notably, the Reserves (2.37 Cr.) exceed the Borrowings (1.56 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.84 | -1.89 | -1.89 | -1.83 | -1.73 | -1.45 | -1.09 | -1.70 | -1.89 | -1.83 | -1.31 | -1.54 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94.68 | 109.20 | 140.04 | 173.48 | 211.25 | 141.18 | 130.62 | 131.85 | 140.02 | 131.52 | 130.16 | 133.93 |
| Inventory Days | 312.46 | 288.16 | 374.86 | 385.66 | 358.71 | 341.26 | 296.56 | 332.62 | 330.51 | 347.34 | 362.08 | 353.03 |
| Days Payable | 105.08 | 118.01 | 98.65 | 182.50 | 330.39 | 163.21 | 159.69 | 129.52 | 152.32 | 170.73 | 29.20 | 83.77 |
| Cash Conversion Cycle | 302.07 | 279.35 | 416.26 | 376.64 | 239.56 | 319.23 | 267.49 | 334.96 | 318.21 | 308.13 | 463.04 | 403.19 |
| Working Capital Days | 222.29 | 142.11 | 467.80 | 428.84 | 417.14 | 387.96 | 449.23 | 477.56 | 503.45 | 477.31 | 639.46 | 731.47 |
| ROCE % | 7.87% | 8.03% | 6.80% | 6.14% | 5.84% | 7.26% | 7.23% | 3.30% | 3.46% | 3.28% | 3.06% | 3.18% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 |
| Diluted EPS (Rs.) | 0.12 | 0.07 | 0.10 | 0.09 | 0.05 |
| Cash EPS (Rs.) | 0.25 | 0.19 | 0.23 | 0.22 | 0.18 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 14.74 | 14.58 | 13.42 | 13.32 | 13.23 |
| Revenue From Operations / Share (Rs.) | 5.45 | 5.66 | 6.37 | 6.13 | 5.85 |
| PBDIT / Share (Rs.) | 0.66 | 0.61 | 0.74 | 0.74 | 0.70 |
| PBIT / Share (Rs.) | 0.56 | 0.51 | 0.60 | 0.60 | 0.57 |
| PBT / Share (Rs.) | 0.19 | 0.13 | 0.13 | 0.12 | 0.09 |
| Net Profit / Share (Rs.) | 0.16 | 0.09 | 0.09 | 0.09 | 0.05 |
| PBDIT Margin (%) | 12.12 | 10.86 | 11.71 | 12.08 | 12.01 |
| PBIT Margin (%) | 10.35 | 9.06 | 9.53 | 9.88 | 9.75 |
| PBT Margin (%) | 3.59 | 2.31 | 2.05 | 2.05 | 1.57 |
| Net Profit Margin (%) | 2.99 | 1.70 | 1.51 | 1.52 | 0.85 |
| Return on Networth / Equity (%) | 1.10 | 0.66 | 0.72 | 0.70 | 0.37 |
| Return on Capital Employeed (%) | 3.70 | 3.32 | 4.05 | 3.89 | 3.82 |
| Return On Assets (%) | 0.88 | 0.53 | 0.49 | 0.47 | 0.26 |
| Long Term Debt / Equity (X) | 0.03 | 0.05 | 0.11 | 0.16 | 0.12 |
| Total Debt / Equity (X) | 0.19 | 0.19 | 0.33 | 0.33 | 0.29 |
| Asset Turnover Ratio (%) | 0.29 | 0.32 | 0.32 | 0.31 | 0.31 |
| Current Ratio (X) | 4.28 | 4.81 | 2.72 | 2.91 | 2.86 |
| Quick Ratio (X) | 3.55 | 3.77 | 2.09 | 2.23 | 2.15 |
| Inventory Turnover Ratio (X) | 2.18 | 1.09 | 1.15 | 1.13 | 1.31 |
| Interest Coverage Ratio (X) | 1.79 | 1.61 | 1.56 | 1.54 | 1.47 |
| Interest Coverage Ratio (Post Tax) (X) | 1.44 | 1.25 | 1.20 | 1.19 | 1.10 |
| Enterprise Value (Cr.) | 6.04 | 13.13 | 7.46 | 5.95 | 4.59 |
| EV / Net Operating Revenue (X) | 2.29 | 4.80 | 2.88 | 2.39 | 1.93 |
| EV / EBITDA (X) | 18.89 | 44.20 | 24.61 | 19.80 | 16.09 |
| MarketCap / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| Price / BV (X) | 0.68 | 1.67 | 1.04 | 0.76 | 0.56 |
| Price / Net Operating Revenue (X) | 1.87 | 4.32 | 2.19 | 1.67 | 1.28 |
| EarningsYield | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Ganga Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 5. It has increased from 0.07 (Mar 24) to 0.12, marking an increase of 0.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.25. This value is below the healthy minimum of 3. It has increased from 0.19 (Mar 24) to 0.25, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 14.74. It has increased from 14.58 (Mar 24) to 14.74, marking an increase of 0.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 5.45. It has decreased from 5.66 (Mar 24) to 5.45, marking a decrease of 0.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 2. It has increased from 0.61 (Mar 24) to 0.66, marking an increase of 0.05.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.56. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.56, marking an increase of 0.05.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 2. It has increased from 0.09 (Mar 24) to 0.16, marking an increase of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.86 (Mar 24) to 12.12, marking an increase of 1.26.
- For PBIT Margin (%), as of Mar 25, the value is 10.35. This value is within the healthy range. It has increased from 9.06 (Mar 24) to 10.35, marking an increase of 1.29.
- For PBT Margin (%), as of Mar 25, the value is 3.59. This value is below the healthy minimum of 10. It has increased from 2.31 (Mar 24) to 3.59, marking an increase of 1.28.
- For Net Profit Margin (%), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 5. It has increased from 1.70 (Mar 24) to 2.99, marking an increase of 1.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 15. It has increased from 0.66 (Mar 24) to 1.10, marking an increase of 0.44.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.70. This value is below the healthy minimum of 10. It has increased from 3.32 (Mar 24) to 3.70, marking an increase of 0.38.
- For Return On Assets (%), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 5. It has increased from 0.53 (Mar 24) to 0.88, marking an increase of 0.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 0.2. It has decreased from 0.05 (Mar 24) to 0.03, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.19.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.29. It has decreased from 0.32 (Mar 24) to 0.29, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 4.28. This value exceeds the healthy maximum of 3. It has decreased from 4.81 (Mar 24) to 4.28, marking a decrease of 0.53.
- For Quick Ratio (X), as of Mar 25, the value is 3.55. This value exceeds the healthy maximum of 2. It has decreased from 3.77 (Mar 24) to 3.55, marking a decrease of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.18. This value is below the healthy minimum of 4. It has increased from 1.09 (Mar 24) to 2.18, marking an increase of 1.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1.79. This value is below the healthy minimum of 3. It has increased from 1.61 (Mar 24) to 1.79, marking an increase of 0.18.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.44. This value is below the healthy minimum of 3. It has increased from 1.25 (Mar 24) to 1.44, marking an increase of 0.19.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.04. It has decreased from 13.13 (Mar 24) to 6.04, marking a decrease of 7.09.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.29. This value is within the healthy range. It has decreased from 4.80 (Mar 24) to 2.29, marking a decrease of 2.51.
- For EV / EBITDA (X), as of Mar 25, the value is 18.89. This value exceeds the healthy maximum of 15. It has decreased from 44.20 (Mar 24) to 18.89, marking a decrease of 25.31.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For Price / BV (X), as of Mar 25, the value is 0.68. This value is below the healthy minimum of 1. It has decreased from 1.67 (Mar 24) to 0.68, marking a decrease of 0.99.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has decreased from 4.32 (Mar 24) to 1.87, marking a decrease of 2.45.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ganga Pharmaceuticals Ltd:
- Net Profit Margin: 2.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.7% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.44
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.55
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 86.2 (Industry average Stock P/E: 51.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.99%
FAQ
What is the intrinsic value of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd's intrinsic value (as of 06 December 2025) is 11.13 which is 4.87% lower the current market price of 11.70, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 6.90 Cr. market cap, FY2025-2026 high/low of 19.2/9.25, reserves of ₹2.37 Cr, and liabilities of 10.16 Cr.
What is the Market Cap of Ganga Pharmaceuticals Ltd?
The Market Cap of Ganga Pharmaceuticals Ltd is 6.90 Cr..
What is the current Stock Price of Ganga Pharmaceuticals Ltd as on 06 December 2025?
The current stock price of Ganga Pharmaceuticals Ltd as on 06 December 2025 is 11.7.
What is the High / Low of Ganga Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ganga Pharmaceuticals Ltd stocks is 19.2/9.25.
What is the Stock P/E of Ganga Pharmaceuticals Ltd?
The Stock P/E of Ganga Pharmaceuticals Ltd is 86.2.
What is the Book Value of Ganga Pharmaceuticals Ltd?
The Book Value of Ganga Pharmaceuticals Ltd is 14.0.
What is the Dividend Yield of Ganga Pharmaceuticals Ltd?
The Dividend Yield of Ganga Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Ganga Pharmaceuticals Ltd?
The ROCE of Ganga Pharmaceuticals Ltd is 3.18 %.
What is the ROE of Ganga Pharmaceuticals Ltd?
The ROE of Ganga Pharmaceuticals Ltd is 1.13 %.
What is the Face Value of Ganga Pharmaceuticals Ltd?
The Face Value of Ganga Pharmaceuticals Ltd is 10.0.